|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FAIR Principles:Interpretations and Implementation Considerations显示文摘The FAIR principles have been widely cited,endorsed and adopted by a broad range of stakeholders since their publication in 2016.By intention,the 15 FAIR guiding principles do not dictate specific technological implementations,but provide guidance for improving Findability,Accessibility,Interoperability and Reusability of digital resources.This has likely contributed to the broad adoption of the FAIR principles,because individual stakeholder communities can implement their own FAIR solutions.However,it has also resulted in inconsistent interpretations that carry the risk of leading to incompatible implementations.Thus,while the FAIR principles are formulated on a high level and may be interpreted and implemented in different ways,for true interoperability we need to support convergence in implementation choices that are widely accessible and(re)-usable.We introduce the concept of FAIR implementation considerations to assist accelerated global participation and convergence towards accessible,robust,widespread and consistent FAIR implementations.Any self-identified stakeholder community may either choose to reuse solutions from existing implementations,or when they spot a gap,accept the challenge to create the needed solution,which,ideally,can be used again by other communities in the future.Here,we provide interpretations and implementation considerations(choices and challenges)for each FAIR principle. | Annika Jacobsen Ricardo de Miranda Azevedo Nick Juty Dominique Batista Simon Coles Ronald Cornet Melanie Courtot Merce Crosas Michel Dumontier Chris T.Evelo Carole Goble Giancarlo Guizzardi Karsten Kryger Hansen Ali Hasnain Kristina Hettne Jaap Heringa Rob W.W.Hooft Melanie Imming Keith G.Jeffery Rajaram Kaliyaperumal Martijn GKersloot Christine R.Kirkpatrick Tobias Kuhn Ignasi Labastida Barbara Magagna PeterMcQuilton Natalie Meyers Annalisa Montesanti Mirjam van Reisen Philippe Rocca-Serra Robert Pergl Susanna-Assunta Sansone Luiz Olavo Bonino da Silva Santos Juliane Schneider George Strawn Mark Thompson Andra Waagmeester Tobias Weigel Mark D.Wilkinson Egon L.Willighagen Peter Wittenburg Marco Roos Barend Mons Erik Schultes | 2020 | Data Intelligence2020，2，1： | 26 |
| 2 | Low-dose metformin treatment in the subacute phase improves the locomotor function of a mouse model of spinal cord injury显示文摘Metformin,a first-line drug for type-2 diabetes,has been shown to improve locomotor recovery after spinal cord injury.However,there are studies reporting no beneficial effect.Recently,we found that high dose of metformin(200 mg/kg,intraperitoneal)and acute phase administration(immediately after injury)led to increased mortality and limited locomotor function recovery.Consequently,we used a lower dose(100 mg/kg,i.p.)metformin in mice,and compared the effect of immediate administration after spinal cord injury(acute phase)with that of administration at 3 days post-injury(subacute phase).Our data showed that metformin treatment starting at the subacute phase significantly improved mouse locomotor function evaluated by Basso Mouse Scale(BMS)scoring.Immunohistochemical studies also revealed significant inhibitions of microglia/macrophage activation and astrogliosis at the lesion site.Furthermore,metformin treatment at the subacute phase reduced neutrophil infiltration.These changes were in parallel with the increased survival rate of spinal neurons in animals treated with metformin.These findings suggest that low-dose metformin treatment for subacute spinal cord injury can effectively improve the functional recovery possibly through anti-inflammation and neuroprotection.This study was approved by the Institute Animal Care and Use Committee at the University of Texas Medical Branch(approval No.1008041C)in 2010. | Wen-Ye Song Han Ding Tiffany Dunn Jun-Ling Gao Javier Allende Labastida Caitlin Schlagal Guang-Zhi Ning Shi-Qing Feng Ping Wu | 2021 | Neural Regeneration Research2021，16，11： | 12 |
| 3 | The“A”of FAIR-As Open as Possible,as Closed as Necessary显示文摘In order to provide responsible access to health data by reconciling benefits of data sharing with privacy rights and ethical and regulatory requirements,Findable,Accessible,Interoperable and Reusable(FAIR)metadata should be developed.According to the H2020 Program Guidelines on FAIR Data,data should be'as open as possible and as closed as necessary','open'in order to foster the reusability and to accelerate research,but at the same time they should be'closed'to safeguard the privacy of the subjects.Additional provisions on the protection of natural persons with regard to the processing of personal data have been endorsed by the European General Data Protection Regulation(GDPR),Reg(EU)2016/679,that came into force in May 2018.This work aims to solve accessibility problems related to the protection of personal data in the digital era and to achieve a responsible access to and responsible use of health data.We strongly suggest associating each data set with FAIR metadata describing both the type of data collected and the accessibility conditions by considering data protection obligations and ethical and regulatory requirements.Finally,an existing FAIR infrastructure component has been used as an example to explain how FAIR metadata could facilitate data sharing while ensuring protection of individuals. | Annalisa Landi Mark Thompson Viviana Giannuzzi Fedele Bonifazi Ignasi Labastida Luiz Olavo Bonino da Silva Santos Marco Roos | 2020 | Data Intelligence2020，2，1： | 4 |
| 4 | Licensing FAIR Data for Reuse显示文摘The last letter of the FAIR acronym stands for Reusability.Data and metadata should be made available with a clear and accessible usage license.But,what are the choices?How can researchers share data and allow reusability?Are all the licenses available for sharing content suitable for data?Data can be covered by different layers of copyright protection making the relationship between data and copyright particularly complex.Some research data can be considered as a work and therefore covered by full copyright while other data can be in the public domain due to their lack of originality.Moreover,a collection of data can be protected by special rights in Europe to acknowledge the investment in time and money in obtaining,presenting,arranging or verifying the data.The need of using a license when sharing data comes from the fact that,under current copyright laws,when rights exist,the absence of any legal notice must be understood as the default“all rights reserved”regime.Unless an exception applies,the authorisation of right holders is necessary for reuse.Right holders could use any text to state the reusability of data but it is advisable to use some of the existing licenses,and especially the ones that are suitable for data and databases.We hope that with this paper we can bring some clarity in relation to the rights involved when sharing research data. | Ignasi Labastida Thomas Margoni | 2020 | Data Intelligence2020，2，1： | 2 |
| 5 | Risk factors involved in symmetrical distal diabetic neuropathy显示文摘 | Viera G N Labastida S Z Silva T H | 2001 | Rev Neurol2001，32，9： | 1 |
| 6 | Conservative management of epithelial ovarian cancer显示文摘 | Dexeus S Labastida R Dexeus D | 2005 | Eur J Gynecol Oncol2005，26，5： | 1 |
| 7 | Conservative management of epithelial ovarian cancer显示文摘 | Dexeus S Labastida R Dexeus D | 2005 | Eur J Gynaecol Oncol2005，5，： | 1 |
| 8 | Preoperative Chemoradiation Therapy and Anal Sphincter Preservation with Locally Advanced Rectal Adenocarcinoma显示文摘 | Pedro Luna-Pérez Saúl Rodríguez-Ramírez Darío F. Rodriguez-Coria Armando Fernández Sonia Labastida Alejandro Silva Marvin J. López | 2001 | World Journal of Surgery2001，，8： | 1 |
| 9 | Endometrial cancer: factors affecting survival 显示文摘 | Labastida R Dexeus S Fabregas R | 2003 | Eur J Gynaecol Oncol2003，24，5： | 1 |
| 10 | Influence of anolyte and catholyte composition on TPHs removal from low permeability soil by electrokinetic reclamation显示文摘 | MURILLO-RIVERA B LABASTIDA I BARRONA J | 2009 | Electrochimica Aeta2009，54，： | 1 |
| 11 | Essure:a new device forhystero-scopic tubal sterilization in an outpatient setting显示文摘 | Ubeda A Labastida R Dexeus S | 2004 | Fertil Steril2004，82，1： | 1 |
| 12 | Reduced - intensity stem cell allografting for PNH patients in the eculizumab era: the Mexican experience 显示文摘 | SCHCOLNIK - CABRERA A LABASTIDA - MERCADO N GALINDO - BECERRA L S | 2015 | Hematology2015，20，5： | 1 |
| 13 | A simple method for displaying Fresnel holograms on liquid crystal panels 显示文摘 | TUDELA R LABASTIDA I MARTIN-BADOSA E | 2002 | Optics Communications2002，214，16： | 1 |
| 14 | Essure:a new device for hysteroscopic tubal sterilization in an outpatient setting 显示文摘 | Ubeda A Labastida R Dexeus S | 2004 | Fertil Steril2004，82，1： | 1 |
| 15 | The surgeon as prognostic factor for local recurrence and survival in the anal sphincter preservation for mid-rectal cancer显示文摘 | Luna PP Reyna HA Labastida AS | 1999 | Rev Invest Clin1999，51，： | 1 |
| 16 | A Simple Method for Displaying Fresnel Holograms on Liquid Crystal Panels 显示文摘 | TUDELA R LABASTIDA I MARTI-BADOSA E | 2002 | Optical Communication2002，214，： | 1 |
| 17 | Full Complex Fresnel Holograms Displayed on Liquid Crystal Devices 显示文摘 | TUDELA R MARTI-BADOSA E LABASTIDA I | 2003 | Journal of Optics A Pure Applied Optics2003，5，： | 1 |
| 18 | Wavefront Reconstruction by Adding Modulation Ca- pabilities of Two Liquid Crystal Devices 显示文摘 | TUDELA R MARTI-BADOSA E LABASTIDA I | 2004 | Optical En- gineering2004，43，11： | 1 |
| 19 | Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy显示文摘 | S. Rodríguez-Cuevas S. Labastida L. Baena F. Gallegos | 1995 | European Archives of Oto - Rhino - Laryngology1995，，3： | 1 |
| 20 | Oral feeding after total laryngeectomy for endolaryngeal cancer显示文摘 | Rodrigues-Cuevas S Labastida S Gutierrez F | 1995 | Eur Arch Otorhinolarngol1995，252，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员